1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: None of our directors or officers adopted , modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended March 31, 2026, as such terms are defined under Item 408(a) of Regulation S-K.
−Removed: 10.1# Employment Agreement dated March 4, 2026, effective as of January 1, 2026, by and between A.J.
−Removed: Kazimi and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 9, 2026.
−Removed: 10.2# Employment Agreement dated March 4, 2026, effective as of January 1, 2026, by and between Jim Herman and Cumberland Pharmaceuticals Inc.
−Removed: incorporated herein by reference to Exhibit 10.12 of the Company’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 9, 2026.
−Removed: 10.3# Employment Agreement dated March 4, 2026, effective as of January 1, 2026, by and between Todd Anthony and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.13 of the Company’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 9, 2026.
−Removed: 10.4# Employment Agreement dated March 4, 2026, effective as of January 1, 2026, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.14 of the Company’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 9, 2026.
−Removed: 10.5# Employment Agreement dated March 4, 2026, effective as of January 1, 2026, by and between John M.
−Removed: Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.15 of the Company’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 9, 2026 .
+Added: None of our directors or officers adopted , modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026, as such terms are defined under Item 408(a) of Regulation S-K.
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: May 8, 2026 By:
+Added: August 7, 2026 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.